Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Relay Therapeutics' Cash from Investing Activities rose 13148.73% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.3 million, marking a year-over-year increase of 189115.64%. This contributed to the annual value of -$41.1 million for FY2024, which is 11594.63% down from last year.
  • Latest data reveals that Relay Therapeutics reported Cash from Investing Activities of $39.7 million as of Q3 2025, which was up 13148.73% from $75.1 million recorded in Q2 2025.
  • Relay Therapeutics' Cash from Investing Activities' 5-year high stood at $75.3 million during Q1 2023, with a 5-year trough of -$292.7 million in Q4 2021.
  • Its 5-year average for Cash from Investing Activities is -$15.5 million, with a median of $29.0 million in 2024.
  • In the last 5 years, Relay Therapeutics' Cash from Investing Activities plummeted by 56380.06% in 2021 and then skyrocketed by 30323.81% in 2025.
  • Quarter analysis of 5 years shows Relay Therapeutics' Cash from Investing Activities stood at -$292.7 million in 2021, then skyrocketed by 49.81% to -$146.9 million in 2022, then skyrocketed by 140.61% to $59.7 million in 2023, then tumbled by 51.41% to $29.0 million in 2024, then surged by 36.99% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $75.1 million for Q2 2025, and $42.5 million during Q1 2025.